Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that an initial one million doses of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine are now available for use in the United Kingdom (U.K.). Nuvaxovid is the first protein-based COVID-19 vaccine granted authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) and will be offered per the Joint Committee on Vaccination and Immunisation (JCVI) advice.
“With U.K. data showing that people infected with both COVID-19 and the flu are more than five times as likely to die compared to someone with no infection1, it is more important than ever to consider any vaccine offered to you by the National Health Service,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “We continue to believe in the importance of a diversified national vaccine portfolio to reduce winter pressures on the health service.”
Nuvaxovid was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein and is formulated with Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response. Nuvaxovid contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
The MHRA granted Conditional Marketing Authorization (CMA) for Nuvaxovid’s use as a two-dose primary series vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults aged 18 and older in February 2022, and in adolescents aged 12 through 17 in August 2022. Novavax submitted a request to the MHRA for expanded CMA of Nuvaxovid as a booster in adults aged 18 and older on June 1, 2022 and is awaiting a decision from the agency.
People In This Post
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more